Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
10.67
+0.32 (3.09%)
Oct 16, 2025, 1:41 PM EDT - Market open
Nurix Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts that cover Nurix Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $28.14, which forecasts a 163.73% increase in the stock price over the next year. The lowest target is $15 and the highest is $35.
Price Target: $28.14 (+163.73%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nurix Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 5 |
| Buy | 8 | 8 | 7 | 7 | 7 | 7 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 16 | 16 | 16 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $16 → $15 | Hold | Maintains | $16 → $15 | +40.58% | Oct 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $34 → $33 | Strong Buy | Maintains | $34 → $33 | +209.28% | Oct 14, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $35 → $32 | Buy | Maintains | $35 → $32 | +199.91% | Oct 10, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $30 → $28 | Buy | Maintains | $30 → $28 | +162.42% | Oct 10, 2025 |
| Oppenheimer | Oppenheimer | Buy Reiterates $32 → $30 | Buy | Reiterates | $32 → $30 | +181.16% | Jul 31, 2025 |
Financial Forecast
Revenue This Year
97.21M
from 54.55M
Increased by 78.20%
Revenue Next Year
62.72M
from 97.21M
Decreased by -35.48%
EPS This Year
-3.04
from -2.88
EPS Next Year
-3.70
from -3.04
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 118.6M | 99.8M | |||
| Avg | 97.2M | 62.7M | |||
| Low | 74.5M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 117.4% | 2.6% | |||
| Avg | 78.2% | -35.5% | |||
| Low | 36.5% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.86 | -2.07 | |||
| Avg | -3.04 | -3.70 | |||
| Low | -3.35 | -4.42 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.